Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

The small molecule CFTR modulators market targets cystic fibrosis treatment, driven by innovative therapies, rising prevalence ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Without Medicaid, the level of care that Walter and other children like him require on an ongoing basis would be inaccessible to families. Yet that is what members of Congress are currently ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic fibrosis (CF), which offer a different mechanism to those sold by market ...